Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch
Patrizia Froeschis currently collaborating with
Istituto Oncologico Svizzera Italiana (IOSI) (Rif. IOSI)
Via Gallino 12 (ex Via Ospedale)
6500 Bellinzona
Patrizia Froesch
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A randomized, multicenter, open label,phase III Study of Lurbinectidin in combonation with Irinotecan versus Investigator’s choice (Topotecan or Irinotecan) in relapsed Small Cell Lung Cancer (SCLC) patients (LAGOON) (Rif. 26000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A randomized, multicenter, open label,phase III Study of Lurbinectidin in combonation with Irinotecan versus Investigator’s choice (Topotecan or Irinotecan) in relapsed Small Cell Lung Cancer (SCLC) patients (LAGOON) (Rif. 26000 202407)
Patrizia Froesch
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non small cell lung cancer (NSCLC). A multicenter phase II trial. (Rif. 27000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non small cell lung cancer (NSCLC). A multicenter phase II trial. (Rif. 27000 202407)
Patrizia Froesch
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer (Rif. 28000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer (Rif. 28000 202407)
Patrizia Froesch
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305). (Rif. 40000 202408)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305). (Rif. 40000 202408)